Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...

The Bank of America Global Healthcare Conference, being held September 23 – 25 in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst led discussion at ...

The on-demand webcast of the company presentation will be available beginning at 7:00 a.m. ET on Friday, September 5, 2025, on the Investors page of Century’s website at www.centurytx.com. The webcast ...

In response to the growing need for addiction recovery services, Renaissance Recovery is expanding its Florida facility with ...

Work has commenced to file a Form 20-F registration statement with the U.S. Securities and Exchange Commission (SEC). CLINUVEL is currently undertaking legal, financial, and regulatory workstreams in ...

Concurrently with the US approval of Vimkunya, Bavarian Nordic was granted a Priority Review Voucher, which was sold for USD 160 million. Upon completion of the sale in July, the Company earned net ...

Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver ...

Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Cantor Global Healthcare Conference 2025 in New York, NY on ...

About BioSyent Inc. Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring ...

VALENCIA, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced ...

Webinar to be held on Wednesday, September 3, 2025 at 4:30 p.m. ET ...

MISSISSAUGA, Ontario, Aug. 21, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three months (Q2) and six months (H1) ended June 30, ...